Dilon Technologies Launches Next-Gen MarginProbe® 2 Device
Dilon Technologies, a prominent name in medical device innovation, has announced an exciting development in the field of breast cancer surgery. The company has gained FDA approval for the MarginProbe® 2 system, marking a significant milestone in intraoperative margin assessment technology. This next-generation device is specifically designed to provide real-time feedback to surgeons during breast-conserving surgeries, ultimately enhancing patient outcomes.
The MarginProbe® 2 is an evolution of its predecessor, which has already established a strong reputation in the market. The original MarginProbe® has been noted for its effectiveness, boasting a reduction in re-excision rates by over 54% on average. With advances made in the new system, the technology features an array of miniaturized sensors and advanced detection algorithms that increase sensitivity to an impressive 76% across all tissue specimens.
Revolutionizing Breast Cancer Surgery
One of the standout features of the MarginProbe® 2 is its ability to detect different types of cancer through options for detecting DCIS (ductal carcinoma in-situ) or invasive cancer. This capability is crucial given that DCIS is responsible for a significant portion of re-excisions, particularly in women aged 18-64 where it accounts for approximately 31% of cases. The system’s user-friendly interface and compatibility with various hospital settings make it a versatile tool for surgeons.
This is a Game-Changer
George Makhoul, the CEO of Dilon Technologies, remarked on the importance of this technology, stating, "MarginProbe® 2 is a game-changer for breast surgery. Our device equips surgeons with immediate margin information, allowing them to make critical decisions right in the operating room. Our ultimate aim is to ensure that surgeons achieve successful outcomes in one operation, minimizing the distress and inconvenience for patients associated with reoperations."
Surgeon Testimonials Highlight the Impact
Surgeons who have already incorporated the MarginProbe® technology into their practices are expressing their satisfaction with its performance. Dr. Vincent Reid from Mercy Hospital commented, "Within 3-5 minutes, I can get immediate results on whether the margins are positive or negative on my specimen. This has helped me maintain a very low re-excision rate of 4.6%."
Dr. Freya Schnabel from NYU Langone shared, "The MarginProbe® is easy to utilize during surgical procedures. The results it provides are straightforward and can be immediately applied, significantly enhancing intraoperative assessments. Its user-friendliness means that any practice can integrate it into their workflow without a steep learning curve."
A Crucial Tool for Reducing Re-excision Rates
Furthermore, Dr. Jaime Alberty from NYC Health and Hospitals System praised the advancements in the system similar to others, indicating, "The improvements in sensitivity without losing specificity are impressive. DCIS remains a major challenge in breast surgery, and anything that can help in reducing re-excision rates proves invaluable in our practice."
Dilon's Commitment to Innovation
This U.S. launch is a testament to Dilon's dedication to improving patient care through innovative solutions. Their robust commercial team is set to showcase this groundbreaking technology across the country, emphasizing its critical role in enhancing surgical precision and patient safety. Hospitals and breast surgeons eager to learn more about the MarginProbe® 2 can explore additional information through various platforms available online.
About Dilon Technologies: Dilon Technologies Inc. is at the forefront of medical device manufacturing, with a mission to enhance the quality of life for patients globally. The company’s diverse and innovative portfolio includes other ground-breaking products like the HEMOBLAST Bellows®, the Navigator™ 2.0 System, and the CoPilot video laryngoscope, all aimed at advancing healthcare solutions. For information about their offerings, visit the Dilon Technologies website.
Frequently Asked Questions
What is the MarginProbe® 2 designed for?
The MarginProbe® 2 is designed for real-time intraoperative margin assessment during breast cancer surgeries, helping reduce re-excision rates.
How does the MarginProbe® 2 increase sensitivity?
The device employs advanced detection algorithms and miniaturized sensors, enhancing its sensitivity to over 76% across various tumors.
What are the benefits of using MarginProbe® 2 for surgeons?
Surgeons benefit by receiving immediate margin information, allowing them to make informed decisions during surgery, thereby improving patient outcomes.
What types of cancer can the MarginProbe® 2 detect?
The device can detect both ductal carcinoma in-situ (DCIS) and invasive cancer, providing crucial information during the surgery.
How can hospitals and surgeons learn more about MarginProbe® 2?
Hospitals and surgeons can obtain more information through Dilon Technologies' website and their nationwide showcases of the technology.
